Lakhasly

Targeted Therapies for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML.) cells contain an abnormal gene, BCR-ABL, that isn't found in normal cells.Some patients may experience an infusion reaction, like an allergic reaction, causing fever, chills, facial flushing, rash, itching skin, vertigo, asthma, and breathing difficulties.The patient cannot eat 2 hours before taking nilotinib and for 1 hour after taking it.

Side effects of nilotinib:

Side effects of nilotinib seem to be mild but can include fluid build-up, lowered blood cell counts, nausea, diarrhea, rash, and some blood chemical changes that may need to be treated (for instance, low potassium and magnesium levels).Side effects of bosutinib:

Common side effects are usually mild and include diarrhea, nausea, vomiting, abdominal (belly) pain, rash, fever, fatigue, and low blood cell counts (including low

platelet counts, low red blood cell counts, and low white blood cell counts).A monoclonal antibody and chemotherapy (chemo) are the usual treatments for chronic lymphocytic leukemia (CLL).Alemtuzumab is given by injection into a vein (intravenous or IV) several times a week, but subcutaneous injections are not approved by the FDA.Side effects during the infusion can be mild, such as itchy chills, fever, nausea, rashes, fatigue, and headaches.Drugs known as tyrosine kinase inhibitors (IKIs) that target BCR-ABL are the standard treatment for CML..Asciminib (Scemblix)

These drugs seem to work best when CML is in the chronic phase, but some can also help patients with more advanced disease (accelerated or blast phases). All these medications have the potential to interact dangerously with over-the-counter vitamins, some other medications, and even some foods (such as

pomegranates and grapefruit).Imatinib

The first medication to precisely target the BCR-ABL tyrosine kinase protein was imatinib (Gleevec).Dasatinib

Dasatinib (Sprycel) is another TKI that targets the BCR-ABL protein.Side effects of dasatinib:

The possible side effects of dasatinib seem to be like those of imatinib, including fluid build-up, lowered blood cell counts, nausea, diarrhea, and skin rashes.Nilotinib

Nilotinib (Tasigna) is another TKI that targets the BCR-ABL protein.Bosutinib:

Bosutinib (Bosulif) is another TKI that targets the BCR-ABL protein.Ponatinib:

Ponatinib (Iclusig) is a TKI targeting the BCR-ABL protein.Asciminib:

Asciminib (Scemblix) is a TKI targeting a very specific area of the BCR-ABL protein.Rituximab is often used along with chemotherapy or targeted drugs, while Ofatumumab is used if CLL is no longer responding to other treatments.More serious side effects can occur during the infusion, including chest pain, heart racing, swelling of the face

and tongue, cough, trouble breathing, dizziness, lightheadedness, or fainting.Tumour lysis syndrome is an uncommon side effect of any of these medications, particularly obinutuzumab, in individuals with extremely high white blood cell counts.Sometimes this resistance can be overcome by increasing the dose of imatinib, but some patients need to change to a different drug, such as one of the other TKIS.This heart rhythm problem can sometimes be caused by nilotinib interacting with other drugs or supplements, so it's especially important to be sure that your cancer doctor knows about any medicines you take, including over-the-counter medicines, vitamins, herbs, and supplements.It can also cause liver problems, including liver failure, as well as pancreatitis (inflammation of the pancreas, which can lead to severe belly pain, nausea, and vomiting).This gene makes a protein, BCR-ABL., which causes CML cells to grow and reproduce out of control.BCR-ABL is a type of protein known as a tyrosine kinase.Make sure your physician always has a current record of all the medications you use, including over-the-counter medications, vitamins, and herbal supplements.A serious side effect that can occur with this drug is fluid build-up around the lung (called a pleural effusion).The fluid can be drained off with a needle, but it can build up again, and the dose of dasatinib may need to be decreased.Side effects of ponatinib:

Most side effects are mild and can include abdominal (belly) pain, headache, rash or other skin problems, and fatigue.There's also a risk of serious blood clots that can lead to heart attacks and strokes, or block arteries and veins in the arms and legs.The risk of serious blood clots is higher in older patients, those with certain risk factors, such as high blood pressure, high cholesterol, or diabetes; and those who have already had a heart attack, stroke, or poor circulation.This drug is used to treat patients with chronic phase CML if two or more other TKIs have already been tried or if their leukemia cells have a gene change called the T3151 mutation.Side effects of asciminib:

The most common side effects of asciminib include feeling tired, nausea, diarrhea, joint and muscle pain, skin rash, and infection of the upper airways.It might also cause some changes to your bloodwork such as a low platelet count, increased triglycerides, low white and red blood cell counts, and abnormal kidney function.Rituximab, Obinutuzumab, and Ofatumumab are some of the main treatments for CLL.Possible side effects include local skin reactions, infections, low white blood cell counts, nausea, fatigue, and constipation.These drugs can cause hepatitis B infections that were dormant to become active again, leading to severe liver problems or even death.This can lead to renal failure and the accumulation of excessive levels of specific minerals in the blood.Alemtuzumab targets the CD52 antigen, which is found on the surface of CLL cells and many T lymphocytes.Skipping pills or adjusting doses can affect the way TKI treatment works.Additionally, you should always confirm the safety of any new medication with your doctor before using it. Furthermore, it's critical to remember that all TKIs have the potential to harm a fetus if used during pregnancy.TKIs are commonly started with chronic phase CML treatment.For chronic phase CML, any of these TKIs could be the first (or frontline) line of treatment.Side effects of imatinib

Common side effects can include diarrhea, nausea, muscle pain, and fatigue.To see if your blood counts improve, your doctor might reduce your imatinib dosage.Imatinib (Gleevec)

2.Dasatinib (Sprycel)

3.cells.

Targeted Therapies for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML.) cells contain an abnormal gene, BCR-ABL, that isn't found in normal cells. This gene makes a protein, BCR-ABL., which causes CML cells to grow and reproduce out of control. BCR-ABL is a type of protein known as a tyrosine kinase. Drugs known as tyrosine kinase inhibitors (IKIs) that target BCR-ABL are the standard treatment for CML.. These include:

1. 
   

   Imatinib (Gleevec)

   
   


2. 
   

   Dasatinib (Sprycel)

   
   


3. 
   

   Nilotinib (Tasigna)

   
   


4. 
   

   Bosutinib (Bosulif)

   
   


5. 
   

   Ponatinib (Iclusig)

   
   


6. 
   

   Asciminib (Scemblix)

   
   

These drugs seem to work best when CML is in the chronic phase, but some can also help patients with more advanced disease (accelerated or blast phases). In most people, the TKIs don't seem to make the leukemia go away forever, so these drugs need to be taken indefinitely. But for some people who have very good, long-lasting responses to treatment, it might be possible to stop taking these drugs, or at least lower the dose. (See Treating Chronic Myeloid Leukemia by Phase to learn more.) These drugs are pills you take at home. To get the best outcomes, it's important to take them exactly the way your doctor tells you to take them. Skipping pills or adjusting doses can affect the way TKI treatment works. See Oral Chemotherapy: What You Need to Know for more on how to best manage cancer treatments you take at home. All these medications have the potential to interact dangerously with over-the-counter vitamins, some other medications, and even some foods (such as

pomegranates and grapefruit). Make sure your physician always has a current record of all the medications you use, including over-the-counter medications, vitamins, and herbal supplements. Additionally, you should always confirm the safety of any new medication with your doctor before using it. Furthermore, it's critical to remember that all TKIs have the potential to harm a fetus if used during pregnancy. TKIs are commonly started with chronic phase CML treatment. For chronic phase CML, any of these TKIs could be the first (or frontline) line of treatment.

Imatinib

The first medication to precisely target the BCR-ABL tyrosine kinase protein was imatinib (Gleevec). Imatinib is taken by mouth as a pill with food, usually once a day. Generic imatinib is also available. Studies have shown that it works as well and causes the same kinds of side effects as the brand name, Gleevec.

Side effects of imatinib

Common side effects can include diarrhea, nausea, muscle pain, and fatigue. These are generally mild. Some people have itchy skin rashes. Most of these symptoms can be treated if needed.

Another common side effect is fluid build-up around the eyes, feet, or abdomen (belly). In rare cases, the fluid may collect in the lungs or around the heart, which can cause trouble breathing. Some studies have suggested that some of this fluid build-up may be caused by the effects of the drug on the heart, though this is rare. It's not yet clear how serious this is or if it might go away if treatment is stopped. If you are taking this drug, tell your doctor right away if you notice sudden weight gain or fluid build-up anywhere in the body or have trouble breathing.

A person may have a decrease in their platelet and white blood cell levels. This may occur during the early stages of treatment because leukemia is causing these blood-

forming cells to produce them. In such a scenario, normal blood-forming cells take over, and blood counts gradually start to increase.

If your blood counts fall too low, your doctor may advise you to temporarily stop taking the medication. This may also occur later during treatment. To see if your blood counts improve, your doctor might reduce your imatinib dosage.

Imatinib appears to gradually stop functioning in certain patients. We refer to this as imatinib resistance. Changes appear to be the root cause of resistance to imatinib. in the genes of the CML. cells. Sometimes this resistance can be overcome by increasing the dose of imatinib, but some patients need to change to a different drug, such as one of the other TKIS.

Dasatinib

Dasatinib (Sprycel) is another TKI that targets the BCR-ABL protein. This drug is a pill taken once a day with or without food. Dasatinib can be used as the first treatment for CML, but it can also be helpful for patients who can't take imatinib because of side effects or because imatinib isn't working.

Side effects of dasatinib:

The possible side effects of dasatinib seem to be like those of imatinib, including fluid build-up, lowered blood cell counts, nausea, diarrhea, and skin rashes.

A serious side effect that can occur with this drug is fluid build-up around the lung (called a pleural effusion). This side effect is more common in patients taking dasatinib twice a day. The fluid can be drained off with a needle, but it can build up again, and the dose of dasatinib may need to be decreased.

Nilotinib

Nilotinib (Tasigna) is another TKI that targets the BCR-ABL protein. This drug can be used as a first treatment for CML and is also used for people who can't take imatinib or whose CML no longer responds to it. It's taken as a pill. The patient cannot eat 2 hours before taking nilotinib and for 1 hour after taking it.

Side effects of nilotinib:

Side effects of nilotinib seem to be mild but can include fluid build-up, lowered blood cell counts, nausea, diarrhea, rash, and some blood chemical changes that may need to be treated (for instance, low potassium and magnesium levels). It can cause high blood sugar and pancreatitis, but this is rare.

This drug can also affect the rhythm of the heart, causing a condition called prolonged QT syndrome. This usually doesn't cause any symptoms but can be serious or even fatal. Because of this, patients should have an electrocardiogram (EKG) before starting nilotinib and then again while being treated. This heart rhythm problem can sometimes be caused by nilotinib interacting with other drugs or supplements, so it's especially important to be sure that your cancer doctor knows about any medicines you take, including over-the-counter medicines, vitamins, herbs, and supplements. You also need to check with your doctor before starting any new medicine, to be sure it's safe. TKIs are used when other TKIs stop working.

Bosutinib:

Bosutinib (Bosulif) is another TKI that targets the BCR-ABL protein. It can be used as the first treatment for CML, but most often it's used if another TKI is no longer working. This drug is taken as a pill with food once a day.

Side effects of bosutinib:

Common side effects are usually mild and include diarrhea, nausea, vomiting, abdominal (belly) pain, rash, fever, fatigue, and low blood cell counts (including low

platelet counts, low red blood cell counts, and low white blood cell counts). Less often, this drug can also cause problems with fluid retention, liver damage, and severe allergic reactions. Your doctor will check your blood test results regularly to watch for problems with your liver and low blood counts.

Ponatinib:

Ponatinib (Iclusig) is a TKI targeting the BCR-ABL protein. Because this drug can cause some serious side effects, it's only used to treat patients with CML if all the other TKIs don't work or if their leukemia cells have a gene change called the T3151 mutation. Ponatinib is one TKI to works against CML cells that have this mutation. This drug is a pill taken once a day with or without food.

Side effects of ponatinib:

Most side effects are mild and can include abdominal (belly) pain, headache, rash or other skin problems, and fatigue. High blood pressure is also common, and it may need to be treated with a blood pressure drug.

There's also a risk of serious blood clots that can lead to heart attacks and strokes, or block arteries and veins in the arms and legs. Rarely, blood clots in patients taking this drug have cut off circulation, and lead to an arm or leg needing to be amputated (cut off). Surgery or another procedure may be needed to treat these blood clots. The risk of serious blood clots is higher in older patients, those with certain risk factors, such as high blood pressure, high cholesterol, or diabetes; and those who have already had a heart attack, stroke, or poor circulation.

Less often, this drug can also weaken the heart muscle, leading to a condition known as congestive heart failure (CHF). It can also cause liver problems, including liver failure, as well as pancreatitis (inflammation of the pancreas, which can lead to severe belly pain, nausea, and vomiting).

Asciminib:

Asciminib (Scemblix) is a TKI targeting a very specific area of the BCR-ABL protein. This drug is used to treat patients with chronic phase CML if two or more other TKIs have already been tried or if their leukemia cells have a gene change called the T3151 mutation. Asciminib is another TKI to works against CML cells that have the T3151 mutation. This drug is a pill taken once a day or twice a day depending on the dose.

Side effects of asciminib:

The most common side effects of asciminib include feeling tired, nausea, diarrhea, joint and muscle pain, skin rash, and infection of the upper airways. It might also cause some changes to your bloodwork such as a low platelet count, increased triglycerides, low white and red blood cell counts, and abnormal kidney function.

A monoclonal antibody and chemotherapy (chemo) are the usual treatments for chronic lymphocytic leukemia (CLL).

Monoclonal antibodies are used to treat CLL, a type of cancer that starts with B lymphocytes. These antibodies target different proteins, such as CD20, which is found on the surface of B lymphocytes. Rituximab, Obinutuzumab, and Ofatumumab are some of the main treatments for CLL. Rituximab is often used along with chemotherapy or targeted drugs, while Ofatumumab is used if CLL is no longer responding to other treatments.

These drugs are given by infusion into a vein (IV), which can take up to several hours depending on the drug. Side effects during the infusion can be mild, such as itchy chills, fever, nausea, rashes, fatigue, and headaches. More serious side effects can occur during the infusion, including chest pain, heart racing, swelling of the face

and tongue, cough, trouble breathing, dizziness, lightheadedness, or fainting. Drugs to prevent these reactions are given before each infusion.

A form of rituximab is given as a shot under the skin, which can take 5 to 7 minutes to inject. Possible side effects include local skin reactions, infections, low white blood cell counts, nausea, fatigue, and constipation. These drugs can cause hepatitis B infections that were dormant to become active again, leading to severe liver problems or even death. Doctors may check blood for signs of an old hepatitis infection before starting this drug. If the blood shows signs of an old hepatitis infection, the drug will need to be stopped.

Tumour lysis syndrome is an uncommon side effect of any of these medications, particularly obinutuzumab, in individuals with extremely high white blood cell counts. This occurs when the medication kills cancer cells so fast that the body finds it difficult to eliminate the byproducts of the dead cells' disintegration. This can lead to renal failure and the accumulation of excessive levels of specific minerals in the blood. Physicians give patients more fluids and medications to prevent this.

Alemtuzumab targets the CD52 antigen, which is found on the surface of CLL cells and many T lymphocytes. It is used mainly if CLL is no longer responding to standard treatments but can also be used earlier in the disease. Alemtuzumab is given by injection into a vein (intravenous or IV) several times a week, but subcutaneous injections are not approved by the FDA. Some patients may experience an infusion reaction, like an allergic reaction, causing fever, chills, facial flushing, rash, itching skin, vertigo, asthma, and breathing difficulties.

Using this medication may result in extremely low white blood cell counts, raising the possibility of serious infections. Antibiotics and antivirals are usually administered to help prevent some of these diseases.